GLP-1 drugs and 'food noise': what the science actually says

What did @goodnoticingspod actually say?

The creator reacted to a viral essay about a woman who ended a friendship after discovering her friend used Wegovy. Their core argument: the essay writer, Sophia Ortega, is someone in eating disorder recovery acting in a way that reflects genuine mental illness, and we should read her behavior through that lens rather than just condemning her. They described eating disorders as a "mental illness where you're like trying to starve yourself practically to death" and argued that the illness "impacts all of your life" beyond just food restriction. Their position was not that Ortega was right, but that she was sick, and that her article gives a useful window into how eating disorder thinking actually works.

The creator also took a swipe at GLP-1 medication framing, describing Wegovy as someone "actively injecting their own body to reject their own hunger cues" -- a phrase lifted from Ortega's perspective, though the creator did not clearly flag that framing as Ortega's rather than their own.

Does the science back this up?

On the eating disorder framing, yes, largely. Anorexia nervosa and related eating disorders are classified as serious mental illnesses with among the highest mortality rates of any psychiatric condition. The claim that they distort "the lens through which you look through everything" tracks well with what researchers actually find. On the GLP-1 framing, it is more complicated.

GLP-1 receptor agonists like semaglutide do affect appetite signaling, but describing them as making the body "reject its own hunger cues" is Ortega's framing, not a clinical description. GLP-1 receptors are present in the brain's appetite-regulating regions, including the hypothalamus and brainstem, and these medications work partly by slowing gastric emptying and modulating satiety signals (Wilding et al., 2021, NEJM). That is not the same as suppressing or rejecting hunger pathologically. People on semaglutide still experience hunger. The mechanism is pharmacological satiety signaling, not starvation-induced suppression.

For people in eating disorder recovery, GLP-1 medications do raise legitimate clinical questions. A 2023 commentary in the International Journal of Eating Disorders (Chesney et al.) noted that patients with restrictive eating disorder histories were generally excluded from major GLP-1 trials, meaning we have limited data on safety and psychological impact in that population.

What did they get wrong (or right)?

They got the broad mental illness framing right. Anorexia nervosa has an estimated mortality rate of around 5-6 per 1,000 person-years, making it one of the deadliest psychiatric conditions (Arcelus et al., 2011, Archives of General Psychiatry). The creator's point that mental illness affects friendships, careers, and "how you move through the world" is clinically sound and often under-discussed in social media discourse that flattens eating disorders into aesthetic or behavioral choices.

What they got muddier: they repeated the phrase "actively injecting their own body to reject their own hunger cues" without adequately challenging it. That framing, coming from someone in restrictive eating disorder recovery, maps GLP-1 medication onto a starvation-adjacent behavior. That is Ortega's perception, shaped by her illness. It is not an accurate pharmacological description. A fact-check has to say that plainly. Letting that phrase float without scrutiny does a disservice to people considering or using GLP-1 medications who are not in that psychological framework.

They also called Ortega "mentally ill" repeatedly in a way that was both clinically accurate and rhetorically sloppy. Accurate because eating disorders are classified mental illnesses. Sloppy because repeating it without nuance can read as dismissive rather than explanatory, which undercuts the compassionate argument they were actually trying to make.

What should you actually know?

If you use GLP-1 medications or are considering them, the social stigma and mischaracterization of how they work is a real problem worth understanding. These medications modulate physiological appetite signaling. They are not the pharmacological equivalent of starvation. Conflating them is a category error that can be harmful both to people who need these treatments and to people in eating disorder recovery trying to make sense of others' choices.

If you have a history of disordered eating, the honest answer from the literature is that GLP-1 medications have not been well-studied in your population. Major trials including the STEP trials for semaglutide excluded patients with active eating disorders. That does not mean these medications are contraindicated for everyone with an eating disorder history, but it does mean any prescribing decision should involve a provider who knows your full history, ideally with coordination from a mental health professional familiar with eating disorder recovery.

The creator's core social observation, that we extend theoretical grace to mental illness in the abstract while withdrawing it when actual mentally ill behavior inconveniences us, is a real tension worth sitting with. It just does not require accepting a distorted description of how GLP-1 medications actually work.